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Interferon y blocks the growth of Toxoplasma gondii in human
fibroblasts by inducing the host cells to degrade tryptophan
(tryptophan/kynurenine/N-formylkynurenine)

E. R. PFEFFERKORN
Department of Microbiology, Dartmouth Medical School, Hanover, NH 03756

Communicated by Walter H. Stockmayer, October 5, 1983

Shimizu (6) have presented evidence that IFN-y is the active
substance in their studies of the inhibition of T. gondii. Experiments done in this laboratory showed that human recombinant IFN-a and IFN-,B had no effect on T. gondii. However, treatment of human fibroblasts with 8 to 16 units of human recombinant IFN-y per ml blocked the growth of T.
gondii. This IFN-y inhibited vesicular stomatitis virus at 4
units/ml with the same line of human fibroblast as host cells
(unpublished data).
The biochemical basis of the antiviral state induced by the
various interferons is now reasonably well understood (reviewed in ref. 7). In reviewing the action of interferon on
nonviral agents, Vildek and Jahiel (2) suggested 13 yr ago
that inhibitory mechanisms different from those that block
viral growth were likely to be involved. This report presents
evidence for an antitoxoplasma mechanism induced by IFNy that is totally different from the well-studied antiviral state
induced by interferons.

Treatment of human fibroblasts with human
ABSTRACT
recombinant y interferon blocked the growth of Toxoplasma
gondii, an obligate intracellular protozoan parasite. Growth of
the parasite was measured by a plaque assay 7 days after infection or by the incorporation of [3HJuracil 1 or 2 days after
infection. The antitoxoplasma activity induced in the host cells
by y interferon was strongly dependent upon the tryptophan
concentration of the medium. Progressively higher minimal inhibitory concentrations of y interferon were observed as the
tryptophan concentration in the culture medium was increased. Treatment with y interferon did not make the cells
impermeable to tryptophan. The kinetics of [3Hltryptophan
uptake into the acid-soluble pools of control and y interferontreated cultures were identical during the first 48 sec. Thereafter uptake of [3Hltryptophan into the acid-soluble pool of control fibroblasts reached the expected plateau after 96 sec. In
contrast, uptake of [3H]tryptophan continued for at least 12
min in the y interferon-treated cultures. At that time, the acidsoluble pool of the y interferon-treated cultures contained 8
times the radioactivity of the control cultures. This continued
accumulation was the result of rapid intracellular degradation
of [3Hltryptophan into kynurenine and N-formylkynurenine
that leaked slowly from the cells. These two metabolites were
also recovered from the medium of cultures treated for 1 or 2
days with y interferon. Human recombinant a and .8 interferons, which have no antitoxoplasma activity, did not induce any
detectable degradation of tryptophan. Several hypotheses are
presented to explain how the intracellular degradation of tryptophan induced by y interferon could restrict the growth of an
obligate intracellular parasite.

MATERIALS AND METHODS
Host Cells and Parasites. Human fibroblasts were grown in
Eagle's (8) minimal essential medium supplemented with
antibiotics and 10% fetal bovine serum. The serum concentration was reduced to 3% for infection or for treatment with
interferon. Medium without tryptophan was prepared from a
kit supplied by GIBCO and supplemented with dialyzed fetal
bovine serum. Cloned T. gondii of the RH strain were maintained by serial passage in human fibroblast cultures and assayed by plaque formation, with the results reported as
plaque-forming units as described (9).
Interferons and Their Titration. Human recombinant IFNa, IFN-p, and IFN-y were supplied by Genentech (San
Francisco, CA) (10). They were stored at 4°C at 106 units/ml
in 0.5 M NaCl/20 mM Tris, pH 8/1% 2-mercaptoethanol. All
interferon concentrations reported here are based on assays
done at Genentech with HeLa cells and vesicular stomatitis
virus. Titrations done in this laboratory with human fibroblasts and vesicular stomatitis virus found these interferons
slightly less potent. The lowest concentrations that suppressed the growth of vesicular stomatitis virus in human
fibroblasts were 2, 2, and 4 units/ml for the IFN-a, IFN-P,
and IFN-y, respectively. Plaque reduction assays (unpublished data) of the activity of IFN-y against T. gondii were
carried out in parallel with every experiment reported here
and always showed complete inhibition of plaque formation
at 8 to 16 units/ml. The extent of the inhibition of the growth
of T. gondii was measured 1 and 2 days after infection by the
incorporation of [3H]uracil. This precursor is incorporated
by T. gondii but not by the host cell because only the parasite contains significant quantities of uracil phosphoribosyltransferase (EC 2.4.2.9) (11). Infected human fibroblast
monolayer cultures in trays that contain 24 wells 1.6 cm in
diameter were labeled by the addition of 5 ,uCi (1 Ci = 37
GBq) of [3H]uracil without changing the medium. Two hours
later the acid-precipitable radioactivity was measured. Because T. gondii has a generation time of 7-8 hr, incorpo-

Interferons are currently assigned to three classes on the basis of the cells that produce them (reviewed in ref. 1); a and X
interferons (IFN-a and IFN-f) are produced by leukocytes
and fibroblasts, respectively, in response to viral infection,
whereas y interferon (IFN-y) is produced by T-lymphocytes
when stimulated by mitogens or by antigens to which they
had previously been sensitized. Each of these interferons
was originally identified through its inhibition of viral
growth. In addition to their well-documented antiviral activities, crude interferons also occasionally have been observed
to suppress the growth of other nonviral intracellular infectious agents (reviewed in ref. 2). In studying the antiviral-like
action of interferon against Toxoplasma gondii, an obligate
intracellular protozoan parasite, it is important that macrophages not be used as the host cells. Activated macrophages
are known to kill intracellular T. gondii (3), and macrophageactivating factor might be present in crude interferon preparations. Indeed, macrophage-activating factor and IFN-y
may well be the same substance. Several laboratories have
reported that interferon blocked the growth of T. gondii in
cultured fibroblast or epithelial cells (4-6). Shirahata and
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
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ration of [3H]uracil during a brief pulse 1 or 2 days after infection is a valid measure of parasite growth. In parallel experiments, the antiparasitic activity of IFN-y measured by
this radiometric assay of T. gondii growth was identical to
the activity obtained by measuring the inhibition of parasite
growth in a plaque assay (unpublished data).
Acid-Soluble Pools. The uptake of [3H]tryptophan into the
acid-soluble pool of human fibroblasts was measured by using confluent cultures grown on round glass coverslips 1.2
cm in diameter. These coverslips were dipped into Hanks'
(12) balanced salt solution to wash away the existing medium
and then incubated at 370C for 6 sec or longer in fresh medium that contained [3H]tryptophan (75 u.Ci/ml). The exposure to this radioactive medium was ended by four successive dips in ice-cold phosphate-buffered saline. The acid-soluble pool was then extracted with cold 0.3 M trichloroacetic
acid for 1 hr. The acid extract was centrifuged at 12,000 x g
for 30 sec, and the radioactivity of the supernatant fluid was
measured.
Chromatography and Electrophoresis. Tryptophan (Rf =
0.65) was separated from a mixture of N-formylkynurenine
and kynurenine (Rf = 0.85) by ascending chromatography on
Whatman 3MM paper in 0.1 M HCl. All three substances
were resolved by a two-dimensional separation that used
thin-layer cellulose ascending chromatography at pH 1.85 in
a solution that contained 0.67 M acetic acid and 0.5 M formic
acid, followed by electrophoresis (50 V/cm) in the same solution without drying the thin layer. Spots were located by
fluorescence under long UV illumination, by the ninhydrin
reaction, or by autoradiography using Kodak XPR-1 x-ray
film.
Charcoal Adsorption. The aromatic compounds in the medium of cultures treated with interferon were concentrated
and desalted by adsorption onto and elution from charcoal.
Medium that had been prepared without phenol red was
shaken with charcoal (1 mg/ml) for 30 min. The charcoal was
collected by centrifugation and washed three times with water. The adsorbed substances were eluted in ammonium hydroxide/ethanol, 8:5 (vol/vol). The eluate was passed
through a 0.22-,um filter to remove residual charcoal and
then evaporated dry under a stream of N2.
Chemicals and Radiochemicals. L-Tryptophan, L-kynurenine, and L-N-formylkynurenine were purchased from Calbiochem. L-[G-3H]Tryptophan (2.8 Ci/mmol) and L-[methylene'4C]tryptophan (58 mCi/mmol) were purchased from Amer-
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FIG. 1. The effect of tryptophan concentration on the inhibition
of the growth of T. gondii in cells treated with IFN-y. Quadruplicate
cultures in 24-well trays were treated with control medium or with
medium that contained 16 units of IFN-y per ml for 24 hr. The cultures were then infected with 3 x 10i plaque-forming units. Twentyfour hours after infection, each culture was labeled with 5 ACi of
[3H]uracil, and the acid-precipitable radioactivity was measured 2 hr
later. e, Control cultures; o, cultures treated with IFN-y.

ished by protein turnover in the absence of this essential
amino acid in the medium.
Fig. 1 shows that the concentration of tryptophan in the
medium markedly affected the antitoxoplasma activity of
IFN- y at 16 units/ml, which was the minimal inhibitory concentration in the titration carried out in Eagle's medium.
Doubling the 10 ,ug of tryptophan found per ml of this medium completely blocked the effect of the IFN-y. This observation was confirmed and extended by titrating the antitoxoplasma activity of IFN-y in media prepared with four different tryptophan concentrations. Fig. 2 shows that these
s100 \

\
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RESULTS
The minimal concentration of IFN-y that blocked the growth
of T. gondii as measured by the specific incorporation of
[3H]uracil was consistently 2-fold higher in Dulbecco's (13)
modified minimal essential medium than it was in Eagle's (8)
original minimal essential medium. Individual tests of each
of the 27 quantitative and qualitative differences between
these two media showed that the critical ingredient was tryptophan, which is supplied at 10 ,ug/ml in Eagle's medium and
16 ,ug/ml in Dulbecco's medium. A systematic analysis of
the dependence of the IFN-y activity upon the tryptophan
concentration in the medium is shown in Fig. 1. The data
from infected cultures that were not treated with IFN-y
showed that the growth of T. gondii was independent of the
tryptophan concentration in the medium. One day after infection, the same incorporation of [3H]uracil was observed
in cultures with tryptophan concentrations that ranged from
0 to 30 ,g/ml. Normal short-term growth of T. gondii within
cells incubated in medium lacking tryptophan does not prove
that the parasite can synthesize this amino acid. T. gondii
may well have grown at the expense of tryptophan in the
acid-soluble pool of the host cell, which would be replen-
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FIG. 2. Titration of the antitoxoplasma activity of IFN-y in media with four tryptophan concentrations. Quadruplicate cultures in
24-well trays were treated with 2-fold dilutions of IFN-y in four media that differed only in tryptophan content. Twenty-four hours later
all cultures were infected with 3 x 104 plaque-forming units; 48 hr
after infection, all cultures were labeled with 5 ,uCi of [3H]uracil, and
the incorporation into acid-precipitable material was measured 2 hr
later. The results are expressed as a percentage of the incorporation
observed in control cultures that were not treated with interferon.
The growth of T. gondii in these cultures was not affected by the
tryptophan content of the media (see Fig. 1). The concentrations of
tryptophan in the media were 0 ,ug/ml (A), 2 ,Ag/ml (A), 10 A.g/ml
(o), and 50 ,Ag/ml (o).
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titrations yielded four roughly parallel curves with progressively more IFN-y required to inhibit the parasite as the
tryptophan concentration in the medium was increased.
The observed interdependence of the tryptophan concentration in the medium and the antitoxoplasma activity induced by IFN-y in human fibroblasts suggested two models.
In the first, interferon induces the host cell to degrade tryptophan. In the second model, interferon induces a defect in
tryptophan transport by host-cell plasma membrane. If T.
gondii, like its host cell, requires tryptophan for growth,
markedly reduced transport of this amino acid by the plasma
membrane of the host cell could result in starvation of the
parasite. Such starvation might even preferentially affect the
parasite because it grows within a cytoplasmic vacuole-the
parasitophorous vacuole-that is thought to be derived, at
least in part, from the plasma membrane of the host cell (14).
If the vacuolar membrane shared the postulated permeability
defect of the plasma membrane, tryptophan in the medium
would have to pass this barrier twice before it could be available to the parasite.
The model of impaired tryptophan transport induced by
IFN-y was tested by comparing the uptake of radioactive
tryptophan into the acid-soluble pools of control and treated
cultures. The acid-soluble pool of the control cultures was
labeled by [3H]tryptophan with the expected kinetics in
which saturation was achieved in about 96 sec (Fig. 3). The
cultures that had been treated with 64 units of IFN-y per ml
for 1 day before measurement of [3H]tryptophan uptake
were identical to the controls during the first 48 sec but
thereafter showed a continued increase in the amount of radioactivity derived from [3H]tryptophan in their acid-soluble
pools. Thus, the model in which IFN-y induces a defect in
tryptophan transport is clearly excluded. However, the increased accumulation of radioactivity in the acid-soluble
pool of cultures treated with IFN-y was a reasonable consequence of the alternative model in which IFN-y induces the
degradation of tryptophan. Degradation of tryptophan would
upset the equilibrium between external and internal
[3H]tryptophan that was established within 96 sec in the control cultures. Rapid intracellular degradation of tryptophan
would result in continued influx of this amino acid from the

(1984)

medium. If the degradation products escaped relatively
slowly from the cells, radioactivity derived from [3H]tryptophan would accumulate in the acid-soluble pool in the manner shown in Fig. 3.
The tryptophan metabolites that accumulate within cells
that were treated with IFN-y do ultimately leak into the medium. When confluent human fibroblasts cultures were treated for 3 days with 64 units of IFN-y per ml of medium that
contained [14C]tryptophan, the cpm/ml of the medium remained approximately the same as measured in daily samples. However, the percentage of the radioactivity that cochromatographed with authentic tryptophan decreased progressively from >95% in control cultures to <20% in
cultures treated with IFN-y for 2 days (Fig. 4). In this latter
sample, most of the radioactivity in the medium migrated
more rapidly than did tryptophan when analyzed by ascending paper chromatography in 0.1 M HCL. Cells treated with
16 units of IFN-y per ml also degraded the tryptophan in
their medium but at a slower rate. In contrast, cultures treated with 1,024 units of human recombinant IFN-a or IFN-,8
per ml showed no degradation of [14C]tryptophan (data not
shown). These interferons do not block the growth of T. gondii (unpublished data).
The first clue as to the identity of the metabolite(s) produced from tryptophan by cells treated with IFN-y was the
observation that the more rapidly migrating material (Fig. 4)
fluoresced when exposed to long UV light. No such rapidly
migrating fluorescent spot was seen on the chromatogram of
control medium. To simplify their identification, the fluorescent tryptophan metabolites were prepared in a highly radioactive form. Two uninfected cultures were treated with 64
units of IFN-y per ml of medium that contained [14C]tryptophan at 10 ,uCi/ml. The medium from these cultures was harvested after 1 and 2 days of incubation, while control medium was harvested from a third culture after 2 days of incubation. Most of the tryptophan from the medium of the culture
treated for 2 days with IFN-y at 64 units/ml was converted
to other radioactive metabolites (Fig. 4).
Trp

,0

4
/

/

/

/

0

/

3
/

0

/

TE
I

/

/

x

/
/

2

/

'a
0

/
/
/
/

0.=2

EV)I
0.

0

0.
E

/

U

1
/

ft

0

cm from origin
5

10

Time, min
FIG. 3. The effect of treatment with IFN-y on the labeling of the
acid-soluble pool of human fibroblasts with [3H]tryptophan. Confluent cultures on coverslips of 1.2-cm diameter were treated with 64
units of IFN-y per ml or with control medium for 24 hr. The coverslip cultures were then dipped briefly into medium that contained 75
ICi of [3H]tryptophan per ml, rinsed quickly, and extracted with
cold trichloroacetic acid. Each point is the average of triplicate determinations. o, Cultures treated with IFN-y; e, control cultures.

FIG. 4. Chromatographic demonstration of the destruction of
tryptophan in the medium of uninfected human fibroblasts treated
with IFN-y. Confluent cultures were treated with medium that contained 64 units of IFN-y per ml or with control medium in the presence of 5 ,uCi of [(4C]tryptophan per ml. Samples of centrifuged medium were supplemented with 2.5 mg of tryptophan per ml and analyzed by ascending paper chromatography in 0.1 M HCL. The
tryptophan spots (Trp) were located through their fluorescence. The
paper chromatographs were cut in 1-cm strips, and the radioactivity
of each strip was determined. *, Control cultures after 2 days of
incubation; o, IFN-y-treated cultures after 1 day of incubation; A,
IFN-y-treated culture after 2 days of incubation.
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Examination of various fluorescent degradation products
of tryptophan showed that most of the radioactivity was associated with two substances, kynurenine and N-formylkynurenine. Part of the evidence for this identification is shown
in Fig. 5, which presents autoradiographs of a two-dimensional thin-layer chromatographic/electrophoretic procedure that completely resolved tryptophan, kynurenine, and
N-formylkynurenine, These three known compounds were
added to the medium samples just before analysis and were
subsequently located by the ninhydrin reaction. All of the
radioactivity in the medium of cultures incubated for 2 days
without interferon migrated with tryptophan (Fig. SA). However, after 1 day of incubation with cells treated with IFN-y,
some of the radioactivity supplied as tryptophan migrated
with kynurenine and N-formylkynurenine (Fig. 5B). Most of
the radioactivity from the medium of cultures treated with
IFN-y for 2 days, migrated with kynurenine, with lesser
amounts associated with N-formylkynurenine and tryptophan. Fig. 5C also shows evidence of several additional minor radioactive metabolites of tryptophan that have not yet
been identified. The identification of the principal radioactive metabolite of tryptophan as kynurenine was confirmed
by observing cochromatography of the authentic compound,
located by ninhydrin, and the 14C-labeled metabolite, locat6-
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FIG. 5. Identification of the principal degradation products of
tryptophan that were released into the medium by cells treated with
IFN-y. Confluent human fibroblast cultures were incubated in medium that contained 64 units of IFN-y per ml or in control medium.
Both media contained 10 ,uCi of [14C]tryptophan per ml. Samples of
the medium were diluted 2-fold with an aqueous solution of tryptophan and kynurenine at 5 mg/ml each and N-formylkynurenine at 10
mg/ml. This mixture was analyzed by two-dimensional thin-layer
chromatography and electrophoresis in a mixture of formic and acetic acids. The radioactive spots on the thin layer were located by
autoradiography with an 8-day exposure. These autoradiograms
contain all of the radioactive spots that were detected. The ninhydrin spots of tryptophan (Trp), kynurenine (K), and N-formylkynurenine (FK) are drawn on the developed x-ray film. (A) Control culture after incubation for 1 day. (B and C). IFN-y-treated cultures
after incubation for 1 day (B) and for 2 days (C).

911

ed by autoradiography, in each of 10 different chromatographic solvents. This identification was further confirmed
by fluorescence spectroscopy with unlabeled material that
had been isolated from the medium of interferon-treated cultures by adsorption onto and elution from charcoal and then
purified by two-dimensional chromatography/electrophoresis. The principal tryptophan metabolite and authentic kynurenine had similar fluorescence emission spectra with the
same maxima.
Once the principal tryptophan metabolites found in the
medium were identified, it was possible to re-examine the
nature of the high level of radioactivity found in the acidsoluble pool of human fibroblasts that had been treated with
IFN-y (Fig. 4). Two-dimensional chromatographic/electrophoretic analyses of the acid-soluble pool extracted 5 min
after exposure to medium that contained [3H]tryptophan
showed that <1% of the intracellular radioactivity was in the
form of tryptophan, while kynurenine and N-formylkynurenine accounted for 30% and 70% respectively.

DISCUSSION
Treatment with IFN-y induced human fibroblasts to degrade
tryptophan. Although the enzymes involved in this degradation have not yet been measured, their identity seems clear
on the basis of the principal tryptophan metabolites isolated
from the medium. The main degradation product of radioactive tryptophan was proven to be kynurenine by cochromatography and coelectrophoresis with the authentic substance
under a wide variety of conditions. This identification was
confirmed by a comparison of fluorescence emission spectra. The second most prominent degradation product, N-formylkynurenine was identified only electrophoretically and
chromatographically. However, the fact that N-formylkynurenine is known to be the biochemical intermediate between tryptophan and kynurenine (Fig. 6) serves to confirm
its identification. Thus IFN-y must, at a minimum, induce an
increase in the activity of the enzyme tryptophan 2,3-dioxygenase (EC 1.13.11.11) that converts tryptophan to N-formylkynurenine. It remains to be determined if the activity of
the second enzyme in the tryptophan degradation pathway,
formamidase (aryl-formylamine amidohydrolase, EC
3.5.1.9) is also increased. It is certainly possible that both of
these enzymes are induced because IFN-y has been reported
to elicit the synthesis of at least three new mRNAs (16) and
six new proteins (17) in addition to those that were induced
also by IFN-a and IFN-,8.
The role of tryptophan degradation in the antitoxoplasma
state induced by IFN-y should first be considered in the context of what is known of the antiviral activities of interferon.
Work in this laboratory has shown that the antitoxoplasma
effect of IFN-y resembles the antiviral action of interferon in
at least three ways (unpublished data). (i) IFN-y has no effect on extracellular parasites. (ii) The host cells must be
treated with IFN-y for -1 day before an antitoxoplasma
state is established. (iii) Once the antitoxoplasma state is established, the medium in which the IFN-y was supplied can
be replaced with normal medium, and the growth of T. gondii is still blocked.
The biochemical bases of the antiviral state induced by the
various interferons are now reasonably well understood (reviewed in ref. 7). Treatment with interferon induces the synthesis of two enzymes, (2'-5')oligo(A) polymerase (designatNH2
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FIG. 6. The pathway from tryptophan to kynurenine as originally defined by Mehler and Knox (15).
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ed (2'-5')A polymerase), and a protein kinase. Each of these
enzymes, when activated by double-stranded RNA made
during viral infection, serves to compromise protein synthesis. The (2'-5')A polymerase makes (2'-5')oligo(A), a series
of short oligonucleotides in which the adenylic acid residues
are linked by a (2'-5')phosphodiester bond. A (2'-5')A polymerase (18, 19) and a kinase (20) that phosphorylates initiation factor eIF-2 are also induced by IFN-y, but their roles in
the antiviral action of this interferon have not been conclusively defined.
The possible antitoxoplasma role of the host cell (2'-5')A
polymerase and protein kinase induced by IFN-y must be
considered with reference to the intracellular site of T. gondii. This parasite grows within a membrane-bound structure,
the parasitophorous vacuole, that lies within the cytoplasm
of its host cell (14). Thus, two barriers that are probably impermeable to proteins, the vacuolar membrane and the plasma membrane of the parasite itself, are interposed between
the cytoplasm of the host cell and that of T. gondii. It is
unlikely that the enzymes induced by interferon have access
to intracellular T. gondii. Similarly, the effector molecule (2'5')oligo(A) would not be expected to cross membranes. T.
gondii is so well insulated from the macromolecules of its
host cell that the antitoxoplasma state induced by IFN-y is
likely to be mediated by substances of low molecular weight.
Further direct evidence that the antiviral proteins that are
induced by all interferons cannot be involved in the antitoxoplasma activity of IFN-y comes from the observation that
only this interferon suppresses the growth of T. gondii. Both
human recombinant IFN-a and IFN-,3 had no antitoxoplasma effect at 1,024 units/ml, the highest concentrations
tested (unpublished data).
The observations reported here provide an alternative biochemical explanation for the antitoxoplasma state produced
in human fibroblasts by IFN-y. As discussed above, treatment with IFN- y induced the degradation of tryptophan into
kynurenine, N-formylkynurenine, and several unidentified
products. It is most unlikely that the interferon-induced degradation of tryptophan and the suppression of the growth of
T. gondii are unrelated events. Any hypotheses that link
these two events must explain the observation that small increases in tryptophan concentration can block the antitoxoplasma activity of a given concentration of IFN-y (Fig. 2). In
constructing these hypotheses, the assumption was made
that T. gondii, like its host cell, was incapable of tryptophan

synthesis.
The intracellular degradation of tryptophan by the host
cell in response to treatment with IFN-y could restrict the
growth of T. gondii in at least two ways. One or more of the
tryptophan metabolites could be toxic to the parasite in a
manner that was reversible by tryptophan. Alternatively, the
degradation of tryptophan could so reduce its concentration
in the acid-soluble pool of the host cell that the intracellular
parasites would be starved for an essential amino acid. The
first of these hypotheses is readily testable by examining the
effect of ultrafiltrates of medium from IFN-ytreated cultures. The low amounts of tryptophan in the acid-soluble
pool of cultures treated with IFN--y provide suggestive evidence for the second hypothesis.
Both crude and purified natural human IFN-y also induce
fibroblasts to degrade tryptophan (unpublished data). However, it remains to be determined if the antitoxoplasma state

Proc. NatL Acad Sci. USA 81

(1984)

produced in vitro by the degradation of tryptophan has any
significance in vivo, where the concentration of tryptophan
in blood is about 7 ug/ml (21). It should be noted that there is
no evidence that infection with T. gondii was needed to trigger the IFN-y-treated cells to degrade tryptophan. The experiments that described this phenomenon were carried out
with uninfected cells. The antiproliferative effect of IFN-y
on cultured cells and its toxic effects in vivo may also be a
consequence of tryptophan degradation and, thus, may be
reversible by an increased supply of this amino acid.
Note Added in Proof. When this manuscript was prepared, I was
unaware of the important observation that high doses of IFN-/3 (104
units/ml) induced indoleamine 2,3-dioxygenase [indoleamine:oxygen 2,3-oxidoreductase (decyclizing)] in mouse lung slices (22). I am
indebted to Dr. Carl Nathan for bringing this work to my attention.
The enzyme induced by physiological doses of INF-y described in
this report is probably also indoleamine dioxygenase.
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